Filgotinib vs adalimumab for rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study compares two RA medications, filgotinib and adalimumab, to see how they affect your body's proteins and genetic signals. It may help your doctor know which treatment is better for your type of RA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 64 years old
- You have moderate to severe rheumatoid arthritis, meaning your joints are quite swollen and painful
- Your doctor is considering treatment with either filgotinib or adalimumab (both are injected or oral medications for RA)
- You have not had a heart attack, stroke, or blood clots
- You are not a current smoker and have not smoked a lot in the past (more than 10 pack-years)
- You are not taking strong bone medications or high-dose steroids for a long time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study compares two treatment options for rheumatoid arthritis (RA): filgotinib or a TNF inhibitor (TNFi). It is designed for adults whose current “standard” RA tablets have not worked well or were not tolerated, to see which approach improves RA control.
This trial uses a very high-strength brain MRI to understand how the RA medicine filgotinib may reduce pain. If you have active rheumatoid arthritis and can safely complete the scan, the study may help researchers better target pain relief in RA.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This trial compares a newer type of medication called JAK inhibitors to standard treatments for rheumatoid arthritis (RA). It aims to see which works better for managing symptoms.
This trial tests if baricitinib, a medication for rheumatoid arthritis, can improve blood clotting issues that some patients with active RA face. It is for adults whose RA is not well-controlled by standard treatments.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.